BLSM (BlossomHill Therapeutics) EV-to-EBIT: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $16.02
View Full Analysis

What is BlossomHill Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BlossomHill Therapeutics's Enterprise Value is $372.03 Mil. BlossomHill Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate BlossomHill Therapeutics's EV-to-EBIT at this moment.

The historical rank and industry rank for BlossomHill Therapeutics's EV-to-EBIT or its related term are showing as below:

BLSM' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.04   Med: 0   Max: 0
Current: -5.81
BLSM's EV-to-EBIT is ranked worse than
100% of 370 companies
in the Biotechnology industry
Industry Median: 15.025 vs BLSM: -5.81

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BlossomHill Therapeutics's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil. BlossomHill Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate BlossomHill Therapeutics's Earnings Yield (Joel Greenblatt) % at this moment.

BlossomHill Therapeutics  (NAS:BLSM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BlossomHill Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2025 ) =EBIT / Enterprise Value (Q: Dec. 2025 )
=/0
= %

BlossomHill Therapeutics EV-to-EBIT Related Terms

BlossomHill Therapeutics EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics EV-to-EBIT Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
EV-to-EBIT
0.00 0.00

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
EV-to-EBIT 0.00 0.00

BLSM vs : EV-to-EBIT Comparison

For the Biotechnology subindustry, BlossomHill Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BlossomHill Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BlossomHill Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BlossomHill Therapeutics's EV-to-EBIT falls into.


BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics EV-to-EBIT Calculation

BlossomHill Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=372.030/
=

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.02
Price